J Clin Endocrinol Metab 103(9):35033506 Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsbll T et al (2019) The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-a review
Y.SchneiderJ
These effects are generally dose-dependent, with higher rates observed at the 2.4 mg weekly dose used for weight management compared to lower doses for diabetes
Furthermore, when compared to patients not taking any of these other medications, the GLP-1 group displayed a recurrence risk of 14.5%, whereas the comparison group had a risk of 51.6%
Growth hormone and IGF-1 signalling favour protein synthesis and longitudinal and radial bone growth, so in long-term lab experiments with Ipamorelin, researchers may observe enlargement of bone structures and an increase in lean muscular tissue mass